To reflect the therapeutic intent and the need for standardised macronutrient targets, the term very-lowcalorie ketogenic diet has been recently revised and replaced with very-lowenergy ketogenic therapy (VLEKT), as proposed by the KetoNut expert panel of the Italian Society of Nutraceuticals (SINut) and the Italian Association of Dietetics and Clinical Nutrition (ADI) [106]

Factors that influence individual response include: Baseline liver function: People with more robust liver enzyme expression may experience less change Dose of retatrutide: Higher doses (8-12 mg) seem to produce more pronounced alcohol effects than lower doses (4-6 mg) Time on medication: Some adaptation occurs over months, though tolerance never returns to pre-medication levels Genetic factors: Variations in Cyp2e1 gene expression affect how dramatically the medication suppresses enzyme activity Body composition changes: As you lose weight on retatrutide, your alcohol distribution volume decreases, independently affecting intoxication The Weight Loss Factor Beyond the direct pharmacological interactions, retatrutides weight loss effects independently change alcohol tolerance
Using the medication beyond that date means youre taking a risk that it might not work properly or could be unsafe
Clinical trials showed A1c reductions of ~0.8%1.0% with albiglutide, a bit less than other GLP-1 RAs, but still significant
Staff is very responsive with any questions I may have, medication has worked better than expected, just spendy